Resumen de la ponencia
DR. MARCO RUGIERO
Vitamin D binding protein-derived macrophage activating factor (GcMAF) is a powerful tool in the immunotherapy of cancer that has proven effective in a variety of cancers. We recently developed an array of novel molecules based on the backbone of GcMAF that mimic its physiological assembly. These novel molecules based on the hydrophobic interaction between GcMAF and oleic acid, were made lethal to cancer cells with an in vitro efficiency about 200 fold higher than the previously known GcMAF preparations. These molecules were designed to resonate in the frequency range of diagnostic ultrasounds in order to be targeted toward the desired areas of the body by properly designed ultrasound probed. With ultrasound guidance, we injected these GcMAF-based molecules in the peritumoral areas of advanced tumours with little vascularisation, or directly into the blood vessels feeding the tumour masses, when present. After the injections, we used ultrasound resonance to target these molecules toward the lesions. Immediately after the injection, a significant, sometimes dramatic, increase in local vascularisation was observed, and we exploited this feature for an additional psycho-oncological visualisation approach to our integrated immunotherapy. In conjunction with glucose deprivation, supplementation of GcMAF-based fermented milk products, and amino acid and vitamin D3 supplementation, we were able to observe reduction in the size of advaced solid tumours up to 50% in about 2 weeks. These results indicate that the approach using ultrasounds and GcMAF-based molecules made lethal to tumour cells is a promising tool in the integrated immunotherapy of advanced tumours.